Literature DB >> 27890442

Predominance of healthcare-associated cases among episodes of community-onset bacteraemia due to extended-spectrum β-lactamase-producing Enterobacteriaceae.

Jean-Ralph Zahar1, Philippe Lesprit2, Stephane Ruckly3, Aurelia Eden4, Hitoto Hikombo5, Louis Bernard6, Stephan Harbarth7, Jean-François Timsit8, Christian Brun-Buisson9.   

Abstract

Extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-PE) are endemic pathogens worldwide. Infection with ESBL-PE may be associated with inadequate antibiotic therapy and a poor outcome. However, risk factors for ESBL-PE community-acquired infections are ill-defined. An observational multicentre study was performed in 50 hospitals to identify the prevalence of and risk factors for community-acquired ESBL-PE bacteraemia. All patients presenting with community-onset Enterobacteriaceae bacteraemia were recorded over a 2-month period (between June and November 2013). Risk factors and 14-day outcomes of patients were investigated. Among 682 Enterobacteriaceae bacteraemia episodes recorded, 58 (8.5%) were caused by ESBL-PE. The most frequent species isolated were Escherichia coli (537; 76.7%) and Klebsiella spp. (68; 9.7%), of which 49 (9.1%) and 8 (11.8%), respectively, were ESBL-producers. Most ESBL-PE episodes were healthcare-associated, and only 22 (38%) were apparently community-acquired. The main risk factor for community-acquired ESBL-PE bacteraemia was a prior hospital stay of ≥5 days within the past year. The overall 14-day survival was 90%; only 4 (6.9%) of 58 patients with ESBL-PE bacteraemia died. Inadequate initial antibiotic therapy was administered to 55% of patients with ESBL-PE bacteraemia but was not associated with increased 14-day mortality. Although many patients had community-onset ESBL-PE bacteraemia, almost two-thirds of the episodes were actually healthcare-associated, and true community-acquired ESBL-PE bacteraemia remains rare. In our essentially non-severely ill population, inappropriate initial therapy was not associated with a higher risk of mortality.
Copyright © 2016 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.

Entities:  

Keywords:  Antibiotic appropriateness; Bacteraemia; Extended-spectrum β-lactamase; Risk factors

Mesh:

Substances:

Year:  2016        PMID: 27890442     DOI: 10.1016/j.ijantimicag.2016.09.032

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  11 in total

1.  Improved quality of care for patients infected or colonised with ESBL-producing Enterobacteriaceae in a French teaching hospital: impact of an interventional prospective study and development of specific tools.

Authors:  Véronique Mondain; Florence Lieutier; Céline Pulcini; Nicolas Degand; Luce Landraud; Raymond Ruimy; Thierry Fosse; Pierre Marie Roger
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-03-28       Impact factor: 3.267

2.  Appropriateness of empirical antibiotic prescription for bloodstream infections in an emergency department from 2006 to 2018: impact of the spread of ESBL-producing Enterobacterales.

Authors:  Marie Clemenceau; Samira Ahmed-Elie; Aurelie Vilfaillot; Richard Chocron; Fabrice Compain; David Lebeaux; Patrick Grohs
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-09-22       Impact factor: 3.267

3.  Amoxicillin/clavulanic acid+aminoglycoside as empirical antibiotic treatment in severe community-acquired infections with diagnostic uncertainty.

Authors:  Johan Courjon; David Chirio; Elisa Demonchy; Céline Michelangeli; Nicolas Degand; Pierre-Marie Roger
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-02-01       Impact factor: 3.267

4.  Bacteraemia in emergency departments: effective antibiotic reassessment is associated with a better outcome.

Authors:  Charlotte Aillet; Didier Jammes; Agnès Fribourg; Sophie Léotard; Olivier Pellat; Patricia Etienne; Dominique Néri; Djamel Lameche; Olivier Pantaloni; Serge Tournoud; Pierre-Marie Roger
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-11-21       Impact factor: 3.267

5.  Risk Factors for Community-Acquired Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae Infections-A Retrospective Study of Symptomatic Urinary Tract Infections.

Authors:  Dheeraj Goyal; Nathan Dean; Sarah Neill; Peter Jones; Kristin Dascomb
Journal:  Open Forum Infect Dis       Date:  2019-01-03       Impact factor: 3.835

6.  Extended spectrum beta-lactamase producing Enterobacterales faecal carriage in a medical intensive care unit: low rates of cross-transmission and infection.

Authors:  Renaud Prevel; Alexandre Boyer; Fatima M'Zali; Thibaut Cockenpot; Agnes Lasheras; Véronique Dubois; Didier Gruson
Journal:  Antimicrob Resist Infect Control       Date:  2019-07-10       Impact factor: 4.887

7.  Fecal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae in hospital and community settings in Chad.

Authors:  Yann Dumont; Sylvain Godreuil; Oumar Ouchar Mahamat; Abdelsalam Tidjani; Manon Lounnas; Mallorie Hide; Julio Benavides; Calèbe Somasse; Abdoul-Salam Ouedraogo; Soufiane Sanou; Christian Carrière; Anne-Laure Bañuls; Hélène Jean-Pierre
Journal:  Antimicrob Resist Infect Control       Date:  2019-10-31       Impact factor: 4.887

Review 8.  Gut Microbiota, Antibiotic Therapy and Antimicrobial Resistance: A Narrative Review.

Authors:  Benoit Pilmis; Alban Le Monnier; Jean-Ralph Zahar
Journal:  Microorganisms       Date:  2020-02-17

9.  Risk Factors for Extended-Spectrum-β-Lactamase-Producing Escherichia coli in Community-Onset Bloodstream Infection: Impact on Long-Term Care Hospitals in Korea.

Authors:  Yae Jee Baek; Young Ah Kim; Dokyun Kim; Jong Hee Shin; Young Uh; Kyeong Seob Shin; Jeong Hwan Shin; Seok Hoon Jeong; Geun Woo Lee; Eun Ji Lee; Dong-Sook Kim; Yoon Soo Park
Journal:  Ann Lab Med       Date:  2021-09-01       Impact factor: 3.464

10.  From Pathophysiological Hypotheses to Case-Control Study Design: Resistance from Antibiotic Exposure in Community-Onset Infections.

Authors:  Salam Abbara; Didier Guillemot; Christian Brun-Buisson; Laurence Watier
Journal:  Antibiotics (Basel)       Date:  2022-02-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.